Overview

Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers

Status:
Completed

Trial end date:
2021-12-06

Target enrollment:
0

Participant gender:
All

Summary

to compare the effectiveness and safety of intralesional vs. systemic MTX in NMSC management

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Zagazig University

Treatments:

Methotrexate

Criteria

Inclusion Criteria:

• Adult patients of both sexes with histologically-confirmed primary or recurrent non-
metastatic NMSCs of different types (BCC,SCC, and/or KA), sites, number, sizes and duration
were included in the study.

Exclusion Criteria:

• Hypersensitivity reactions to methotrexate, liver or kidney disease, immunosuppressive
conditions, HIV, HBV, and HCV infection, hematological abnormalities and metastasis.
Pregnant or lactating women, females in their child-bearing period not using or refusing
contraceptive methods, and those who had any other form of NMSC management in the month
preceding enrollment.